Endocrine Abstracts

Background: GI neuroendocrine tumors express somatostatin (SSTR) receptors, and the radioloabeled SSTR analog Lu-177-DOTATATE is an FDA-approved systemic treatment for those with metastatic disease. Olaparib is a poly (ADP-ribose) polymerase inhibitor (PARPi) which inhibits cells from repairing damaged DNA, especially single-stranded DNA breaks caused by beta particle emissions from the radioactive decay of Lu-177. We report the first results of a phase 1/2 study evaluating th...

Background: Metastatic GI Neuroendocrine Tumors (GI-NET) and pheochromocytoma/paraganglioma (PPGL) are are tumors which overexpresses somatostatin receptors (SSTR) and can be treated with targeted radioligand therapy (RLT) such as Lu-177-DOTATATE. However, despite demonstrated clinical efficacy at stabilizing tumor growth, durable response is very rare and almost all patients inevitably progresses at some time after treatment. Good systemic therapy options after beta-emiting R...

Background: Pheochromocytoma/Paraganglioma (PPGL) are rare neuroendocrine tumors that expresses somatostatin receptors (SSTR) and can be treated with radiolabeled somatostatin analogues such as Lu-177-DOTATATE. Ga-68-DOTATATE PET scans show the distribution and density of SSTR+ tumors, and F-18-FDG PET scans show hypermetabolism in lesions. Total uptake volumes (TUV) for each respective scan can be obtained consistently and semi-automatically using standardized workflow in ima...

Background: Pheochromocytoma/Paraganglioma (PPGL) are rare neuroendocrine tumors that expresses somatostatin receptors (SSTR) and can be treated with radiolabeled somatostatin analogues such as Lu-177-DOTATATE. This study is the first prospective study to examine the safety and efficacy of Lu-177-DOTATATE in the treatment of metastatic or inoperable PPGL in a phase 2 clinical trial setting, and results from a planned interim analysis are presented.Method...

Background: Somatostatin receptors (SSTR) is overexpressed in a number of different tumors, including GI Neuroendocrine Tumors (GI-NET), Pheochromocytoma/Paraganglioma (PPGL), small cell lung cancer (SCLC), renal cell carcinoma (RCC), and certain head and neck cancers (H&N) such as olfactory neuroblastoma. It has been demonstrated that these SSTR-expressing tumors can be treated with beta-emitting radioligand therapy (RLT) that binds to SSTR such as Lu-177-DOTATATE. Howeve...